Clinical Trial Update: A Safety and Efficacy Study of E10030 (Anti-PDGF Pegylated Aptamer) Plus Lucentis for Neovascular Age-Related Macular Degeneration [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating E10030 (Anti-PDGF pegylated aptamer) plus Lucentis for neovascular age-related macular degeneration has completed with results p…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Age-related Macular Degeneration

Drugs mentioned

• E10030 (Anti-PDGF pegylated aptamer) (anti-PDGF pegylated aptamer)
• Lucentis (ranibizumab)

Snippet

Sponsor: Ophthotech Corporation | Conditions: Age-Related Macular Degeneration | Phase 2 | Status: COMPLETED | Results posted: 2014-01-03